Cerebral and splenic infarctions after injection of N-butyl-2-cyanoacrylate in esophageal variceal bleeding.

Abstract

Variceal bleeding is the most serious complication of portal hypertension, and it accounts for approximately one fifth to one third of all deaths in liver cirrhosis patients. Currently, endoscopic treatment remains the predominant method for the prevention and treatment of variceal bleeding. Endoscopic treatments include band ligation and injection sclerotherapy. Injection sclerotherapy with N-butyl-2-cyanoacrylate has been successfully used to treat variceal bleeding. Although injection sclerotherapy with N-butyl-2-cyanoacrylate provides effective treatment for variceal bleeding, injection of N-butyl-2-cyanoacrylate is associated with a variety of complications, including systemic embolization. Herein, we report a case of cerebral and splenic infarctions after the injection of N-butyl-2-cyanoacrylate to treat esophageal variceal bleeding.

• Authors: Dae-Seong Myung, Cho-Yun Chung, Hyung-Chul Park, Jong-Sun Kim, Sung-Bum Cho, Wan-Sik Lee, Sung-Kyu Choi, Young-Eun Joo
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 19 Issue 34 Pg. 5759-62 (Sep 14 2013) ISSN: 2219-2840 [Electronic] United States
• PMID: 24039373 (Publication Type: Case Reports, Journal Article)

Chemical References

• Enbucrilate

Topics

• Cerebral Infarction (etiology)
• Enbucrilate (administration & dosage, adverse effects)
• Esophageal and Gastric Varices (complications, therapy)
• Female
• Gastrointestinal Hemorrhage (etiology, therapy)
• Humans
• Injections
• Middle Aged
• Sclerotherapy (adverse effects)
• Splenic Infarction (etiology)